<DOC>
	<DOCNO>NCT00603239</DOCNO>
	<brief_summary>This study ass safety efficacy exenatide combination thiazolidinedione ( TZD ) TZD plus metformin 26 week adult patient type 2 diabetes achieve adequate glycemic control .</brief_summary>
	<brief_title>Safety Efficacy Exenatide Patients With Type 2 Diabetes Using Thiazolidinedione Thiazolidinedione Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Diagnosed type 2 diabetes If treat thiazolidinedione ( TZD ) alone , TZD dose must stable least 120 day The dose TZD must : Rosiglitazone ( ≥4 mg/day ) pioglitazone ( ≥30 mg/day ) The metformin dose stable least 90 day Have suboptimal glycemic control evidence HbA1c 7.1 % 10.0 % , inclusive . Have body mass index ( BMI ) : 25 kg/m2 &lt; BMI &lt; 45 kg/m2 . Have participate study previously study use exenatide ( AC2993/LY2148568 ) glucagonlike peptide1 ( GLP1 ) analog , previously treat exenatide GLP1 analog Have participate interventional medical , surgical , pharmaceutical study ( study experimental , drug , medical , surgical treatment give ) within 30 day screen . This criterion include drug receive regulatory approval indication time study entry . Have treat exogenous insulin 1 week within 2 month prior screen Used drug weight loss ( e.g. , orlistat , rimonabant , sibutramine , similar overthecounter medication ) within 3 month prior screen . Are currently treat follow excluded medication : Sulfonylurea meglitinide derivative ( e.g. , repaglinide nateglinide ) within 3 month prior screen Alphaglucosidase inhibitor ( e.g. , miglitol acarbose ) within 3 month screen Dipeptidyl peptidase4 ( DPP4 ) inhibitor ( e.g. , sitagliptin vildagliptin ) within 3 month prior screen Pramlintide acetate injection within 3 month prior screen Drugs directly affect gastrointestinal motility , include , limited : Metoclopramide , cisapride , chronic macrolide antibiotic Are receive chronic ( lasting longer 2 week ) systemic glucocorticoid therapy ( exclude topical inhale preparation ) receive therapy within 4 week immediately precede study start</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exenatide</keyword>
	<keyword>metformin</keyword>
	<keyword>thiazolidinedione</keyword>
	<keyword>Byetta</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>